1. Medtech Insight
  2. >>Archive

Reimbursement In Brief

CMS opens national coverage analysis for PET tracers to diagnose dementia. HHS Office of Inspector General reports on prosthetics and orthotics payments. More reimbursement news.

The agency seeks comments through Nov. 8 on an external request to expand Medicare coverage for positron emission tomography (PET) tracers to agents that image beta-amyloid plaques to diagnose dementia and other neurogenerative diseases. CMS opened the national coverage analysis Oct. 9 in response to a June 29 letter from Eli Lilly & Co.

Lilly asks CMS to update its national coverage policy to authorize the use of PET with a radiopharmaceutical such as the company’s recently FDA-approved Amyvid (florbetapir F 18), to diagnose...

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.